Immune Complexes and Human Cancer, the fifteenth volume of Contem porary Topics in Immunobiology, is a compilation of information derived from recent studies on the role of circulating immune complexes (CIC) in the patho genic manifestations of a variety of human cancers. Technical improvements in the detection of CIC in body fluids have resulted in data that indicate that CIC do occur in different types of cancer. In addition, tumor-associated antigens and antibodies have been detected in immune complexes of cancer patients' sera. Until recently the exact role and clinical relevance of immune…mehr
Immune Complexes and Human Cancer, the fifteenth volume of Contem porary Topics in Immunobiology, is a compilation of information derived from recent studies on the role of circulating immune complexes (CIC) in the patho genic manifestations of a variety of human cancers. Technical improvements in the detection of CIC in body fluids have resulted in data that indicate that CIC do occur in different types of cancer. In addition, tumor-associated antigens and antibodies have been detected in immune complexes of cancer patients' sera. Until recently the exact role and clinical relevance of immune complexes have been the subject of debate, partially because of the problems encountered in measuring immune complexes. But these problems are being confronted as more accurate measurement protocols are developed. Technical refinements, along with strict protocols, have provided evidence of heterogeneity in CIC, a factor that makes accurate detection of immune complexes in cancer patients difficult. Recent insights indicate that the measurement of immune complexes in cancer patients may be clinically useful not only as a tumor marker, but also in regard to the deranged immune response of tumor-bearing hosts and other disorders such as nephrotic syndrome, immune anemias, and clotting dysfunction.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
1 Clinical Significance and Nature of Circulating Immune Complexes in Melanoma Patients.- I. Introduction.- II. CIC Detection Methods in Cancer.- III. Incidence of CIC in Melanoma Patients.- IV. Clinical Application of CIC Analysis in Melanoma.- V. Nature of CIC in Melanoma Patients.- VI. Concluding Remarks.- VII. References.- 2 Clinical Relevance of Immune Complexes, Associated Antigen, and Antibody in Cancer.- I. Introduction.- II. Incidence of Immune Complexes in Cancer.- III. Etiology of Immune Complexes.- IV. Pathogenetic Effects of CIC.- V. Role of CIC as Tumor Markers.- VI. Therapeutic Role of Immune Complexes.- VII. Overview and Concluding Remarks.- VIII. References.- 3 The Pathophysiology of Circulating Immune Complexes: Their Role in Host-Tumor Interactions and Removal by Immunoadsorption Therapy.- I. Introduction.- II. Antiimmunoglobulins and Their Effect on the Variety of CIC Formed in the Plasma of Cancer Patients.- III. Interactions of CIC and Complement with the Clotting, Kinin, and Fibrinolyic Systems.- IV. Interaction of CIC with Platelets and Red Blood Cells.- V. The Role of CIC in Lymphocyte Function.- VI. Clinical Significance of CIC in Cancer Patients.- VII. Clinical Treatment Modalities for the Removal of CIC.- VIII. References.- 4 Immune Complexes in Patients Bearing Solid Tumors.- I. Introduction.- II. Detection of CIC.- III. CIC in the Sera of Cancer Patients.- IV. Overview and Conclusion.- V. References.- 5 Immunosuppressor Control as a Modality of Cancer Treatment: Effect of Plasma Adsorption with Staphylococcus aureus Protein A.- I. Introduction.- II. Cellular and Humoral Immunosuppressive Mechanisms in the Tumor-Host Relationship.- III. Soluble Immune Complexes as Predominating Immunosuppressor Molecules in Tumor-Bearing Hosts.- IV. PossibleMechanism of Generation of Immunosuppressive Factors in the Tumor-Bearing Host.- V. Immunotherapy by Controlling the Suppressor Cell Function.- VI. Nature of Specific Plasma Blocking Factors in the Tumor Host.- VII. Control of Serum Blocking Factors as an Approach to Cancer Immunotherapy.- VIII. Plasma Adsorption in Rats Bearing a Chemically Induced Mammary Adenocarcinoma.- IX. Plasma Adsorption in Dogs Bearing a Transplantable Canine Venereal Tumor and Various Spontaneously Occurring Tumors.- X. Plasma Adsorption in Human Cancer Patients.- XI. Possible Mechanisms of Tumor Regression in Plasma-Adsorbed Hosts-An Imbalance in the Dynamic Equilibrium of Immune Complexes Activating the Host Immunity to Fight Cancer.- XII. Infusion of Purified Protein A Showing Effect Similar to Plasma Adsorption.- XIII. Enterotoxin Contamination of Protein A and Its Possible Effects.- XIV. Possible Mechanism of Generation of Various Bioreactive Products following Plasma Adsorption over S. aureus or S. aureus Wood 46 and during Direct Infusion of Protein A.- XV. Summary.- XVI. References.- 6 Blocking (Suppressor) Factors, Immune Complexes, and Extracorporeal Immunoadsorption in Tumor Immunity.- I. Introduction.- II. Specific Blocking Factors.- III. Immune Complexes in Cancer.- IV. Relationship between SBF and Suppressor Cells.- V. Analysis of Suppressor Factors Produced Using Hybridoma Technology.- VI. Immune Modulation by Plasma Treatment: Rationale and Major Findings.- VII. Lymphosarcoma and Persistent FeLV Infection of Pet Cats: A Model to Study Immunological Responses during Extracorporeal Immunoadsorption Treatments.- VIII. Extracorporeal Immunoadsorption Treatments of AIDS-like Syndromes.- IX. Conclusions.- X. References.- 7 Trials of Staphylococcal Protein A-Treated PlasmaInfusions in Cancer Therapy: Clinical Effects and Implications for Mode of Action.- I. Introduction and Background.- II. Methodology.- III. Results.- IV. Discussion of Results and Implications for Mode of Action.- V. Summary.- VI. References.- 8 Protein A Immunoadsorption/Immunoactivation: A Critical Review.- I. Introduction.- II. In Vivo Studies in Laboratory Animals.- III. Clinical Studies.- IV. In Vitro Investigations.- V. Discussion and Conclusions.- VI. References.
1 Clinical Significance and Nature of Circulating Immune Complexes in Melanoma Patients.- I. Introduction.- II. CIC Detection Methods in Cancer.- III. Incidence of CIC in Melanoma Patients.- IV. Clinical Application of CIC Analysis in Melanoma.- V. Nature of CIC in Melanoma Patients.- VI. Concluding Remarks.- VII. References.- 2 Clinical Relevance of Immune Complexes, Associated Antigen, and Antibody in Cancer.- I. Introduction.- II. Incidence of Immune Complexes in Cancer.- III. Etiology of Immune Complexes.- IV. Pathogenetic Effects of CIC.- V. Role of CIC as Tumor Markers.- VI. Therapeutic Role of Immune Complexes.- VII. Overview and Concluding Remarks.- VIII. References.- 3 The Pathophysiology of Circulating Immune Complexes: Their Role in Host-Tumor Interactions and Removal by Immunoadsorption Therapy.- I. Introduction.- II. Antiimmunoglobulins and Their Effect on the Variety of CIC Formed in the Plasma of Cancer Patients.- III. Interactions of CIC and Complement with the Clotting, Kinin, and Fibrinolyic Systems.- IV. Interaction of CIC with Platelets and Red Blood Cells.- V. The Role of CIC in Lymphocyte Function.- VI. Clinical Significance of CIC in Cancer Patients.- VII. Clinical Treatment Modalities for the Removal of CIC.- VIII. References.- 4 Immune Complexes in Patients Bearing Solid Tumors.- I. Introduction.- II. Detection of CIC.- III. CIC in the Sera of Cancer Patients.- IV. Overview and Conclusion.- V. References.- 5 Immunosuppressor Control as a Modality of Cancer Treatment: Effect of Plasma Adsorption with Staphylococcus aureus Protein A.- I. Introduction.- II. Cellular and Humoral Immunosuppressive Mechanisms in the Tumor-Host Relationship.- III. Soluble Immune Complexes as Predominating Immunosuppressor Molecules in Tumor-Bearing Hosts.- IV. PossibleMechanism of Generation of Immunosuppressive Factors in the Tumor-Bearing Host.- V. Immunotherapy by Controlling the Suppressor Cell Function.- VI. Nature of Specific Plasma Blocking Factors in the Tumor Host.- VII. Control of Serum Blocking Factors as an Approach to Cancer Immunotherapy.- VIII. Plasma Adsorption in Rats Bearing a Chemically Induced Mammary Adenocarcinoma.- IX. Plasma Adsorption in Dogs Bearing a Transplantable Canine Venereal Tumor and Various Spontaneously Occurring Tumors.- X. Plasma Adsorption in Human Cancer Patients.- XI. Possible Mechanisms of Tumor Regression in Plasma-Adsorbed Hosts-An Imbalance in the Dynamic Equilibrium of Immune Complexes Activating the Host Immunity to Fight Cancer.- XII. Infusion of Purified Protein A Showing Effect Similar to Plasma Adsorption.- XIII. Enterotoxin Contamination of Protein A and Its Possible Effects.- XIV. Possible Mechanism of Generation of Various Bioreactive Products following Plasma Adsorption over S. aureus or S. aureus Wood 46 and during Direct Infusion of Protein A.- XV. Summary.- XVI. References.- 6 Blocking (Suppressor) Factors, Immune Complexes, and Extracorporeal Immunoadsorption in Tumor Immunity.- I. Introduction.- II. Specific Blocking Factors.- III. Immune Complexes in Cancer.- IV. Relationship between SBF and Suppressor Cells.- V. Analysis of Suppressor Factors Produced Using Hybridoma Technology.- VI. Immune Modulation by Plasma Treatment: Rationale and Major Findings.- VII. Lymphosarcoma and Persistent FeLV Infection of Pet Cats: A Model to Study Immunological Responses during Extracorporeal Immunoadsorption Treatments.- VIII. Extracorporeal Immunoadsorption Treatments of AIDS-like Syndromes.- IX. Conclusions.- X. References.- 7 Trials of Staphylococcal Protein A-Treated PlasmaInfusions in Cancer Therapy: Clinical Effects and Implications for Mode of Action.- I. Introduction and Background.- II. Methodology.- III. Results.- IV. Discussion of Results and Implications for Mode of Action.- V. Summary.- VI. References.- 8 Protein A Immunoadsorption/Immunoactivation: A Critical Review.- I. Introduction.- II. In Vivo Studies in Laboratory Animals.- III. Clinical Studies.- IV. In Vitro Investigations.- V. Discussion and Conclusions.- VI. References.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
